0000000000517427

AUTHOR

Antonio Vita

showing 2 related works from this author

Real-world evidence from a European cohort study of patients with treatment resistant depression:Healthcare resource utilization

2022

Journal of affective disorders 298, Part A 442-450 (2022). doi:10.1016/j.jad.2021.11.004 special issue: "Special Issue on Corona Virus / Edited by Allan Young, Ron Acierno, Xiang Yang Zhang"

Healthcare resource utilization Major depressive disorder Observational study Real-world evidence Treatment resistant depressionmedicine.medical_specialtyMajor depressive disorderTreatment resistant depressionCohort StudiesIndirect costsDepressive Disorder Treatment-ResistantHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depressionObservational studyHealth careHealthcare resource utilizationmedicineHumansMajor depressive episodeDepression (differential diagnoses)Retrospective StudiesReal-world evidenceDepressive DisorderDepressive Disorder Majorbusiness.industryTreatment-ResistantMajorHealth Care Costsmedicine.diseasePsychiatry and Mental healthClinical PsychologyEmergency medicineMajor depressive disorderObservational studymedicine.symptombusinessHealthcare resource utilization; Major depressive disorder; Observational study; Real-world evidence; Treatment resistant depression; Cohort Studies; Delivery of Health Care; Health Care Costs; Humans; Retrospective Studies; Depressive Disorder Major; Depressive Disorder Treatment-ResistantTreatment-resistant depressionDelivery of Health CareCohort study
researchProduct

Real-world effectiveness of long acting aripiprazole: Treatment persistence and its correlates in the Italian clinical practice

2019

Abstract Objectives To identify the variables that are associated with persistence to Aripiprazole-Long Acting (A-LAI), in adult patients with schizophrenia. Methods Observational, retrospective, non-interventional study involving 261 patients with schizophrenia. Results Eighty-six percent of study subjects were persistent for at least 6 months. All subjects with baseline CGI-S of 1 or 2, 95% of subjects with CGI-S of 3, 86% with CGI-S of 4, 82% of subjects with CGI-S of 5, 73% of subjects with CGI of 6 and 90% of subjects with CGI of 7 were persistent. A-LAI treatment continuation rate was higher in patients with: 1) baseline CGI score ≤ 4; 2) schizophrenia dimension (LDPS) mania score ≤ 5…

Long actingMaleAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Psychiatry and Mental Health; Biological PsychiatryAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized; Adult; Antipsychotic Agents; Aripiprazole; Delayed-Action Preparations; Female; Humans; Italy; Male; Medication Adherence; Middle Aged; Retrospective Studies; Schizophrenia; Treatment OutcomePersonalizedAripiprazole0302 clinical medicineRetrospective StudieDelayed-Action PreparationMaintenaMiddle AgedhumanitiesClinical PracticeTreatment OutcomeItalySchizophreniaPsychiatry and Mental HealthAripiprazoleFemaleBiological psychiatrymedicine.symptomManiaHumanmedicine.drugAntipsychotic AgentsAdultmedicine.medical_specialtyMedication AdherencePersistence03 medical and health scienceshealth services administrationInternal medicinemental disordersmedicineTreatment persistenceHumansBiological PsychiatryRetrospective Studiesbusiness.industryRetrospective cohort studymedicine.diseaseAdherence; Aripiprazole; Long acting; Maintena; Persistence; Personalized;030227 psychiatryAntipsychotic AgentLong actingAdherenceDelayed-Action PreparationsSchizophreniabusiness030217 neurology & neurosurgery
researchProduct